Rosa Ayala

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3688398/publications.pdf

Version: 2024-02-01

89 papers	1,843 citations	361296 20 h-index	289141 40 g-index
91 all docs	91 docs citations	91 times ranked	3542 citing authors

#	Article	IF	Citations
1	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 2014, 123, 3073-3079.	0.6	380
2	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia, 2014, 28, 823-829.	3.3	148
3	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 2016, 101, 926-931.	1.7	118
4	Clinical course and risk factors for mortality from COVIDâ€19 in patients with haematological malignancies. European Journal of Haematology, 2020, 105, 597-607.	1.1	73
5	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica, 2011, 96, 1470-1477.	1.7	59
6	Evaluation of minimal residual disease in multiple myeloma patients by fluorescentâ€polymerase chain reaction: the prognostic impact of achieving molecular response. British Journal of Haematology, 2008, 142, 766-774.	1.2	52
7	Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients. BMC Gastroenterology, 2012, 12, 114.	0.8	50
8	Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Annals of Hematology, 2015, 94, 911-918.	0.8	49
9	High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations. Journal of Molecular Diagnostics, 2009, 11, 155-161.	1.2	48
10	Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia, 2017, 31, 1446-1449.	3.3	44
11	Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Annals of Hematology, 2008, 87, 741-749.	0.8	43
12	Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies. International Journal of Molecular Sciences, 2019, 20, 2832.	1.8	42
13	Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget, 2017, 8, 106948-106961.	0.8	38
14	Breast Cancerâ€“Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High-Dose Chemotherapy With Peripheral Blood Stem Cell Support. Journal of Clinical Oncology, 2006, 24, 3611-3618.	0.8	36
15	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica, 2019, 104, 288-296.	1.7	36
16	Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events. Journal of Atherosclerosis and Thrombosis, 2016, 23, 1242-1253.	0.9	32
17	Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients. BMC Gastroenterology, 2011, 11, 130.	0.8	31
18	Clinical applicability and prognostic significance of molecular response assessed by fluorescentâ€<scp>PCR</scp> of immunoglobulin genes in multiple myeloma. Results from a <scp>GEM</scp>/<scp>PETHEMA</scp> study. British Journal of Haematology, 2013, 163, 581-589.	1.2	27

#	Article	IF	Citations
19	Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer Journal, 2021, 11, 198.	2.8	25
20	MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. Scientific Reports, 2019, 9, 18630.	1.6	24
21	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. Journal of Molecular Diagnostics, 2019, 21, 228-240.	1.2	24
22	Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covidâ€19 patients. International Journal of Laboratory Hematology, 2021, 43, O152-O155.	0.7	23
23	Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Annals of Hematology, 2017, 96, 1069-1075.	0.8	21
24	Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. Journal of Clinical Pathology, 2011, 64, 1010-1013.	1.0	20
25	Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. Molecular Cancer, 2013, 12, 142.	7.9	20
26	Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. British Journal of Haematology, 2013, 161, 667-676.	1.2	20
27	High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers. Journal of Medical Genetics, 2020, 57, 269-273.	1.5	20
28	Long-term follow-up of donor chimerism and tolerance after human liver transplantation. Liver Transplantation, 2009, 15, 581-591.	1.3	19
29	Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?. Annals of Hematology, 2018, 97, 2089-2098.	0.8	18
30	Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse. Haematologica, 2021, 106, 2325-2333.	1.7	18
31	miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. Leukemia, 2020, 34, 2648-2659.	3.3	18
32	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Advances, 2021, 5, 760-770.	2.5	18
33	Living Donor Liver Transplantation: Usefulness of Hemostatic and Prothrombotic Screening in Potential Donors. Transplantation Proceedings, 2009, 41, 3791-3795.	0.3	16
34	The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies. Cancers, 2022, 14, 1310.	1.7	16
35	<scp>CALR</scp> mutations screening should not be studied in splanchnic vein thrombosis. British Journal of Haematology, 2015, 170, 588-589.	1.2	15
36	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. Haematologica, 2021, 106, 3079-3089.	1.7	15

#	Article	IF	Citations
37	Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genetics, 2012, 205, 190-191.	0.2	14
38	Realâ€world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer, 2022, 128, 2441-2448.	2.0	14
39	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica, 2018, 103, e544-e548.	1.7	13
40	Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. British Journal of Haematology, 2020, 189, 672-683.	1.2	11
41	Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. Scientific Reports, 2021, 11, 20745.	1.6	11
42	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics. Blood Cancer Journal, 2020, 10, 43.	2.8	10
43	Leucemia mieloide crÃ³nica en EspaÃ±a: sus caracterÃsticas de presentaciÃ³n han cambiado. SecciÃ³n espaÃ±ola del registro poblacional EUTOS. Revista Clinica Espanola, 2016, 216, 293-300.	0.2	9
44	PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. PLoS ONE, 2017, 12, e0181366.	1.1	8
45	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. Scientific Reports, 2020, 10, 5904.	1.6	8
46	Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. Annals of Hematology, 2011, 90, 939-946.	0.8	7
47	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. Cancers, 2021, 13, 2458.	1.7	7
48	The use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma. International Journal of Laboratory Hematology, 2004, 26, 31-35.	0.2	6
49	Realâ€time PCR quantification of haematopoietic chimerism after transplantation: a comparison between TaqMan and hybridization probes technologies. International Journal of Laboratory Hematology, 2010, 32, e17-25.	0.7	6
50	Simplifying the detection of MUTYH mutations by high resolution melting analysis. BMC Cancer, 2010, 10, 408.	1.1	5
51	Acute myeloid leukemia and transcription factors: role of erythroid KrÃ¼ppel-like factor (EKLF). Cancer Cell International, 2012, 12, 25.	1.8	5
52	Use of <scp>S</scp>orafenib as an effective treatment in an <scp>AML</scp> patient carrying a new point mutation affecting the <scp>J</scp>uxtamembrane domain of <scp>FLT</scp>3. British Journal of Haematology, 2012, 158, 555-558.	1.2	5
53	Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. Annals of Hematology, 2015, 94, 1237-1239.	0.8	5
54	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma. Cancers, 2020, 12, 3304.	1.7	5

#	Article	IF	Citations
55	Wilms Tumor 1 gene expression levels improve risk stratification in <scp>AML</scp> patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. British Journal of Haematology, 2018, 181, 542-546.	1.2	4
56	Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy. Antioxidants, 2019, 8, 508.	2.2	4
57	JAK2 exon 12 mutations were not found in liver transplant recipients with or without pretransplant portal vein thrombosis. European Journal of Gastroenterology and Hepatology, 2014, 26, 362-363.	0.8	3
58	CaracterÃsticas clÃnico-biolÃ³gicas de los pacientes con mielofibrosis: un anÃ¡lisis de 1.000 casos del Registro EspaÃ±ol de Mielofibrosis. Medicina ClÃnica, 2020, 155, 152-158.	0.3	3
59	A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. Leukemia, 2021, 35, 3295-3298.	3.3	2
60	Prognostic heterogeneity of adult Bâ€cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3â€PBX1 treated with measurable residual diseaseâ€oriented protocols. British Journal of Haematology, 2021, , .	1.2	2
61	Grupos de riesgo citogenÃ©tico en la leucemia mieloide aguda: comparaciÃ³n de los modelos adoptados por los grupos MRC (Medical Research Council, del Reino Unido) y SWOG (Southwest Oncology) Tj ETQq1 1 0.784314 rgBT /Overloc	0.3	2
62	Post-Transplant Myelodysplastic Syndromes In Pediatric Liver Transplantation Recipients: a Report of Two Cases. Blood, 2010, 116, 4978-4978.	0.6	2
63	Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. Blood, 2021, 138, 4041-4041.	0.6	2
64	MPL S505C enhances driver mutations at W515 in essential thrombocythemia. Blood Cancer Journal, 2021, 11, 188.	2.8	2
65	Minimal Residual Disease Monitoring from Liquid Biopsy By Next Generation Sequencing in Follicular Lymphoma Patients. Blood, 2020, 136, 31-33.	0.6	2
66	Application of Self-Quenched JH Consensus Primers for Real-Time Quantitative PCR of IGH Gene to Minimal Residual Disease Evaluation in Multiple Myeloma. Journal of Molecular Diagnostics, 2006, 8, 364-370.	1.2	1
67	Detection of Emerging Resistant Clones in Philadelphia-Positive Leukemia Patients Exposed to Tyrosine Kinase Inhibitors. Correlation of cDNA and Gdna Approaches. Blood, 2020, 136, 6-8.	0.6	1
68	Jumping Translocation in a Patient with Acute Leukemia and Fatal Evolution. Case Reports in Oncology, 2020, 13, 1026-1030.	0.3	0
69	Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology. Leukemia Research, 2021, 108, 106613.	0.4	0
70	Importance of JAK2 V617F Allele Burden in the Diagnosis of Myeloproliferative Diseases and Its Association to Age.. Blood, 2007, 110, 4654-4654.	0.6	0
71	Long-Term Follow-up of Donor Chimerism and Tolerance After Human Liver Transplantation.. Blood, 2009, 114, 3534-3534.	0.6	0
72	Ocena minimalnej choroby resztkowej w szpiczaku plazmocytowym. Hematologia, 2017, 8, 219-227.	0.0	0

#	Article	IF	Citations
73	rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling. Blood, 2018, 132, 3072-3072.	0.6	0
74	Study of the Clinical Significance of the Length of FLT3-ITD in Acute Myeloid Leukemia Patients. Blood, 2018, 132, 5278-5278.	0.6	0
75	Protein Carbonylation Pattern Is Altered in Myelodisplastic Syndromes. Blood, 2018, 132, 5502-5502.	0.6	0
76	Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients. Blood, 2019, 134, 5368-5368.	0.6	0
77	Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study). Blood, 2019, 134, 5904-5904.	0.6	0
78	Clinical Course and Risk Factors for Mortality from COVID-19 in Patients with Hematological Malignancies. SSRN Electronic Journal, 0, , .	0.4	0
79	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. Blood, 2021, 138, 608-608.	0.6	0
80	Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group. Blood, 2021, 138, 1302-1302.	0.6	0
81	Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC). Blood, 2021, 138, 3655-3655.	0.6	0
82	Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH. Blood, 2021, 138, 4491-4491.	0.6	0
83	Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML). Blood, 2021, 138, 520-520.	0.6	0
84	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. Blood, 2021, 138, 3438-3438.	0.6	0
85	The Spliceosome As a New Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia. Blood, 2021, 138, 3334-3334.	0.6	0
86	Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial. Blood, 2020, 136, 32-32.	0.6	0
87	Study of the Role of Splicing Factor SRRM2 in Cytarabine Treatment Resistance in Acute Myeloid Leukemia. Blood, 2020, 136, 8-9.	0.6	0
88	Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia. Blood, 2020, 136, 4-5.	0.6	0
89	Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 136, 41-42.	0.6	0